Related Experiment Videos
Regulatory T cells in lupus
1Division of Rheumatology, Departments of Medicine and Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
International Reviews of Immunology
|March 15, 2006
Summary
Early-life regulatory T cells control organ-specific autoimmunity but not lupus. Therapeutic approaches inducing adaptive regulatory T cells show promise for lupus treatment.
Area of Science:
- Immunology
- Autoimmunity
- T cell biology
Background:
- Naturally occurring CD4+ CD25+ regulatory T cells are crucial for organ-specific autoimmune disease control.
- These thymic-exported regulatory T cells may not be sufficient for suppressing systemic autoimmunity in lupus.
- Lupus-prone individuals often exhibit deficiencies in generating adaptive T-regulatory cells.
Purpose of the Study:
- To review autoantigen-specific therapeutic strategies for inducing regulatory T cells in lupus.
- To highlight the potential of TGF-β-producing regulatory T cells in lupus treatment.
Main Methods:
- Investigating autoantigen-specific therapeutic approaches.
- Utilizing low-dose tolerance therapy with nucleosomal histone peptide epitopes in lupus-prone mice.
- Administering subcutaneous injections in subnanomolar doses.
Main Results:
- Therapy induced TGF-β-producing CD4+ CD25+ and CD8+ regulatory T cells.
- These regulatory T cells effectively suppressed autoantigen recognition and autoantibody production.
- Regulatory T cells inhibited pathogenic autoimmune cell migration to target organs like kidneys.
Conclusions:
- Autoantigen-specific induction of regulatory T cells represents a promising therapeutic avenue for lupus.
- TGF-β-producing regulatory T cells demonstrate efficacy in preclinical lupus models.
- Further investigation is warranted to determine the clinical applicability in lupus patients.